IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Immuron Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026
$0.96−0.03 (-2.62%)
Close on Oct 19, 2026
Share price
−$1.2536 (−56.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Immuron Ltd grew revenue 5.9% to A$7.71M over fiscal 2026. Free cash flow was -A$3.26M.
Revenue
A$7.71M
+5.9% vs. a year earlier
Operating income
-A$3.85M
FY2026
Free cash flow
-A$3.26M
FY2026
EPS, diluted
-1.24 AUD
FY2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- A$7.71M
- Net income
- -A$3.68M
- EPS, diluted
- -1.24 AUD
- Free cash flow
- -A$3.26M
Valuation needs the share price. It fills in once daily prices are connected and converted from AUD.
Twelve years at a glance
Fiscal years 2015 to 2026, AUD
Revenue
A$7.71M+5.9% YoY
Gross profit
A$4.98M+4.4% YoY
Operating income
-A$3.85M
Net income
-A$3.68M
EPS, diluted
-1.24 AUD
Free cash flow
-A$3.26M
Reported period